Generate Biomedicines, Inc. (GENB) vs Personalis, Inc. (PSNL)
A side-by-side comparison of Generate Biomedicines, Inc. and Personalis, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GENB
Generate Biomedicines, Inc.
$14.16HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
PSNL
Personalis, Inc.
$15.97HealthcareDelayed quote: Oct 6, 2026, 12:50 PM EDT
Total return — GENB vs PSNL
growth of $100 · dividends reinvested · last 1yGENB +10.0% (+10.0%/yr)PSNL +81.6% (+81.6%/yr)PSNL compounded faster over this window
GENB PSNL
GENB vs PSNL: by the numbers
- •GENB is the larger company ($1.82B vs $1.70B market cap).
- •Both run net losses; PSNL's is the smaller (-153.84% vs -636.99% net margin).
Metrics side by side
Valuation
| Metric | GENB | PSNL |
|---|---|---|
| P/S ratio | N/A | 24.46 |
| P/B ratio | 3.98 | 7.25 |
Profitability
| Metric | GENB | PSNL |
|---|---|---|
| Gross margin | 100.00% | 22.65% |
| Operating margin | -737.04% | -126.43% |
| Net margin | -636.99% | -153.84% |
| ROE | N/A | -45.58% |
| ROIC | -94.79% | -42.87% |
Growth (annualized)
| Metric | GENB | PSNL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -3.33% |
| Total return CAGR (5Y) | N/A | -1.75% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.